Treatment for cutaneous T-cell lymphoma (CTCL) is increasingly tailored to disease stage and location. Early-stage skin-only disease is often treated with phototherapy, while advanced disease may require systemic therapies such as romidepsin, pralatrexate, or Brentuximab vedotin.
A key option for advanced CTCL is Mogamulizumab-kpkc, particularly for patients with high blood involvement or Sezary syndrome. In the MAVORIC trial, the drug showed strong blood responses of about 70%, compared with 40% in the skin and 20% in lymph nodes. Blood improvement can occur within weeks, while skin responses often take around three months.
Doctors also monitor for a treatment-related rash that can resemble disease progression. Because patients with rash may respond better to therapy, clinicians often manage symptoms with steroids or methotrexate instead of stopping treatment.